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Elucidating protein–protein interactions has been a
central feature to understanding intracellular signal
transduction. Many of the binding sites of the
interacting proteins in these pathways are within highly
sequentially homologous and structurally conserved
domains. We challenge the dogma that mutual
exclusivity in signalling is derived from a high level of
specificity in these domains. 
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The process whereby activation of a membrane-localised
receptor leads to a signal being conveyed through the
cytoplasm, giving rise to a cellular response, is dominated
by a series of protein–protein interactions. For a given sig-
nalling pathway, such as that based on tyrosine kinase
activity, the current dogma holds that activating the recep-
tor gives rise to a linear pathway. The activated receptor
therefore interacts with one protein that in turn interacts
with a downstream effector or adaptor protein. Subse-
quently, a series of bimolecular interactions produce a
relay of interactions that occur right down to the nucleus
and ultimately result in a cellular response. This dogma
has largely arisen because it provides a simple explanation
and because of the types of experiments that have been
used to address the issue of signal transduction. For
example, immuno-precipitation experiments under most
conditions will only show the protein(s) that interact(s)
directly with the designated protein of interest.
A linear signalling process requires that the interactions
between the molecules in the transduction pathway are
highly specific and do not allow the passage of the signal if
interaction with the wrong upstream activator occurs.
Perhaps the most extensively studied system exemplify-
ing the necessity for specificity is that involving the tyro-
sine-kinase-mediated pathways. One prominent feature of
the proteins involved in interactions in these pathways is
that many of them contain similar structurally indepen-
dent domains (for example SH2, SH3, PH and PTK;
reviewed in [1]). Because similar domains are present in
different pathways, which give rise to very different cellu-
lar responses, it suggests that a high level of specificity
must prevail in the interactions of these domains. It is very
difficult, however, to see how this exquisite specificity
arises because the domains show such high sequence and
structural homology. The interactions of SH2 and SH3
domains form the focus of this discussion of specificity.
Specificity in SH2 domains
SH2 domains consist of ~100 amino acids that fold into a
structure dominated by a β sheet sandwiched by a pair of
α helices (see, for example, [2]). The role of SH2
domains in intracellular signal transduction was shown to
be centred around the interaction with proteins that have
phosphorylated tyrosine residues (pY). These interac-
tions can, potentially, be mimicked by tyrosyl phospho-
peptides. High-resolution structural studies reveal that
the basis for this binding involves the insertion of pY into
a deep pocket on the SH2 domain. The pockets are, for
the most part, very similar in all SH2 domains, forming
an anchoring point for the ligand but offering nothing in
the way of specificity. A highly conserved arginine
residue interacts with one of the negative charges on the
phosphate group, pinning it into the pocket. The tyrosyl
phosphopeptide is generally held in an extended confor-
mation, but there are a few exceptions, such as in the
binding of peptides to the SH2 domain of Grb2. Struc-
tural studies reveal that, in this case, the peptide adopts a
β-turn conformation (see Figure 1a) [2].
The identification of many proteins containing SH2
domains revealed their role in mediating different linear
signalling pathways that produce diverse cellular responses.
The involvement of SH2-containing proteins in different
pathways suggested that there was an inherent specificity
associated with their interactions. Studies using tyrosyl
phosphopeptides with random sequences proximal to the
pY appeared to reveal where this specificity emanated from.
The interactions of individual SH2 domains were shown to
have preferences for a given sequence of amino acids,
either amino- or carboxy-terminal of the pY. In many cases
the interaction of the third residue carboxy-terminal of the
pY (pY + 3) was deemed important [1]. For example, the
SH2 domain of Src was shown to require the sequence
pYEEI (using single-letter amino-acid code), whereas the
amino-terminal SH2 domain from the p85 subunit of PI3-
kinase recognised the sequence pYMXM (where X is any
amino acid) [3]. The experiments that determined these
preferences by their nature (i.e. using successive rounds of
binding, washing and hence enrichment of the library
towards tighter binding epitopes) would inevitably select
tighter binding ligands, but the level of difference in affin-
ity that this corresponds to does not have to be high.
Crosstalk R3
Searching for specificity in SH domains
John E Ladbury1 and Stefan Arold2
cm7105.qxd  02/08/2000  01:29  Page R3
R4 Chemistry & Biology 2000, Vol 7 No 1
The expected high level of specificity should be reflected
in a large difference in the binding affinity of a specific
compared with a nonspecific ligand for a given SH2
domain. A series of interactions have been studied using a
variety of SH2 domains and tyrosyl phosphopeptides.
These studies showed that the difference between a so-
called specific and a nonspecific interaction amounts to less
than two orders of magnitude in affinity. For example,
Table 1 shows the binding data for interactions of a range of
tyrosyl phosphopeptides with the SH2 domain from the
protein Src. These data raise the question of whether the
specificity demonstrated in these peptide-binding studies
is sufficient to guarantee mutual exclusivity in signalling
pathways in cells that might have numerous SH2-domain-
containing proteins. For example, the peptide based on the
platelet-derived growth factor (PDGF) receptor (with the
motif pYVPM) binds to the SH2 domain only about an
order of magnitude less tightly than the peptides contain-
ing the specific pYEEI motif. Thus, potentially in the pres-
ence of high, localised concentrations in a given cell line
the PDGF receptor would compete for the Src SH2
domain at the expense of the physiological ligand. Activa-
tion of Src through stimulation of the PDGF receptor could
therefore result, leading to an erroneous signal. Table 1 also
reveals that the expected specificity from the interaction in
the pY + 3 pocket is very limited and makes little apparent
difference to the overall binding. Furthermore, the binding
of a peptide that has a sequence very different from that of
the specific peptide, such as that of the carboxyl terminus
of Src (pYQPG), binds with an affinity only of approxi-
mately two orders of magnitude weaker.
The literature reveals many additional examples in which
different peptide sequences do not seem to bind to SH2
Figure 1
(a) Space-filling models of SH2 domains from four proteins. The
binding surfaces are shown with the nonpolar (green), polar (grey) and
charged (positive – blue; negative – red) residues highlighted. Despite
the SH2 domains being from proteins from varied signalling pathways
the similarity of the binding surfaces is dramatic. (b) Focusing in on the
binding sites of the SH2 domains shown in (a) to highlight the
similarities of the surfaces as are experienced by potential ligands.
Table 1
Binding of Src SH2 domains to tyrosyl phosphopeptides.
Tyrosyl phosphopeptide KD (µM) Reference
KGGQpYEEIPIP* 0.55 [20]
EPQpYEEIPIYL† 0.09 [21]
EPQpYEEI 0.18 [22]
PQpYEEIPI 0.20 [23]
PEGDpYEEVL 0.16 [22]
EPQpYEEVPIYL 0.16 [21]
EPQpYEEEPIYL 0.21 [21]
TQpYVPMLE‡ 5.88 [23]
EPQpYQPGEN§ 14.3 [21]
PQpYQPGEN 29.4 [23]
All binding studies were performed under the following conditions
unless indicated: 25°C and 20 mM MES buffer, 50 mM NaCl, pH 6.0.
10 mM HEPES, 90 mM NaCl, pH 7.4. †Derived from the hamster
middle T antigen; ‡derived from the platelet-derived growth factor
receptor; §derived from the carboxy-terminal sequence of Src. Bold
indicates key residues involved in recognition by the SH2 domain.
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domains with high levels of specificity. The tyrosyl phos-
phopeptides GHDGpYQGLSTATK and ATKDTpYDA-
LHMQA bind to the SH2 domain from Shc with KD
values of 50 µM and 650 µM, respectively [4]. This differ-
ence of little more than an order of magnitude for two
apparently quite different peptides suggests a low level of
discrimination in binding.
Some level of promiscuity in SH2 domain binding has
been demonstrated in in vivo studies. Mutations in the
SH2 domain of Sem-5 produce a vulva-less phenotype in
Caenorhabditis elegans. A chimeric form of Sem-5 in which
the SH2 domain was replaced by that of Src was able to
rescue vulval development at nearly 30% of the wild-type
efficiency on micro-injection into a cell line containing a
strong sem-5 allele displaying the completely vulva-less
phenotype. The ability of the SH2 domain from a very
different protein to rescue activity by binding to the site
on the receptor defined as specific for Sem-5 emphasises
that the level of specificity is not very high [5].
The lack of specificity in these interactions might be
expected when one considers the binding sites presented
to ligands by SH2 domains from a variety of proteins
(Figure 1). It is clear from the alignment of these proteins
showing the positively (blue) and negatively (red) charged,
the nonpolar (green) and polar (light grey) residues in the
binding sites that a potential ligand does not have much to
distinguish one site from another. The general topology of
the sites is very similar; the flexible peptide traverses a
hydrophobic patch with a stripe of polar residues running
vertically across it. In all the structures there is a positively
charged patch that includes a highly conserved arginine
residue, which accommodates the pY phosphate moiety
(see above). Figure 1b shows the region occupied by the
peptide on the SH2 domain surface. The alignment of all
the peptide sites shows that they all have very similar fea-
tures. A possible analogy to this would be to consider the
peptide as an aircraft searching for its required landing
field (the cognate SH2 domain binding site). On looking
at Figure 1b there is little identify the airport to the pilot.
Specificity in SH3 domains
Like SH2 domains, SH3 domains play a role in the locali-
sation of proteins to defined sites, anchoring them through
interactions with sites containing proline-rich amino acid
sequences. The first reports of ligands for SH3 domains
demonstrated that large polypeptides containing these
sequences could bind more tightly than short peptides
containing the proline-rich sequence in isolation [6,7]. It
was generally accepted, however, that the specificity in
binding was dominated by the proline-rich regions alone
Figure 2
Space-filling models of SH2 domains from
four proteins. The binding surfaces are shown
with the nonpolar (green), polar (grey) and
charged (positive – blue; negative – red)
residues highlighted. Again, as with the SH2
domains, although the SH3 domains being
from proteins from varied signalling pathways
the similarity of the binding surfaces is clear.
The surface within the black dots represents
an area on the surface of the Fyn SH3 domain
where additional interactions have been
observed in the structure of the complex with
Nef (see text for details).
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(other interactions were largely forgotten). Differences in
binding motifs containing the sequence PXXP were
shown to offer different levels of specificity.
The SH3 domain structure consists largely of two β sheets
that form a partly open β barrel. Structural studies have
revealed that the binding site for the proline-rich motif is a
largely featureless hydrophobic patch (Figure 2). The
issue of specificity of ligands for SH3 domains was again
addressed using an approach based on screening with
limited random peptide libraries (e.g., [8,9]). Peptide
binding studies suggest that some additional specificity
could emanate from some residues carboxy-terminal of the
proline-rich motif. This was emphasised in studies
showing that for some SH3 domains the proline-rich
peptide could be orientated in two opposed directions
depending on the flanking sequence of the residues in the
peptide [10,11]. There are a large number of reports of the
binding of peptides to SH3 domains from a variety of pro-
teins and these generally confirm that differences in KD
values only encompass about two orders of magnitude
(Table 2). As with the SH2 domain interactions, there
does not seem to be a high level of specificity invoked.
For example, the SH3 domain from Fyn binds equally
well to peptides bearing the proline-rich motifs from Sos
and the p85 subunit of PI3-kinase. This SH3 domain
(based on binding studies with peptides) cannot, there-
fore, discriminate between binding sites on two very dif-
ferent proteins that occur in the same cell lines. Structural
details on SH3 domains in complex with intact proteins
suggest that other interactions outside those mimicked by
peptides might be important [12], but binding studies
suggest that affinities do not increase by more than an
order of magnitude when additional interactions are
incurred [13]. Furthermore, in one of these studies the
SH3 domain interacts with a viral protein (Nef) that has
potentially evolved a mechanism to exploit additional
interactions to allow it to better compete with pre-existing
cellular proteins [14] (Figure 2).
As in the SH2 domain, the SH3 binding site has few distin-
guishing features among SH3 domains from a diverse
sample of proteins (Figure 2). The bound peptide appears
to follow a hydrophobic furrow running along the surface of
the domain. All the domains seem to have a pair of nega-
tively charged patches, one of which forms a recognition
site for a positively charged residue if it appears in the
PXXP motif (e.g. arginine in the sequence from Nef
PLRP). Again, the pilot trying to identify the correct
landing strip would struggle to identify whether a particu-
lar binding site was London Heathrow or London Gatwick.
Is the specificity in SH domain interactions sufficient?
For both SH2 and SH3 domains the difference between a
specific and a nonspecific interaction is less than two
orders of magnitude in affinity. A difference in KD of
approximately two orders of magnitude in some interac-
tions is considered to be specific. For example, the differ-
ence between a specific interaction and a nonspecific
interaction for gene repressor proteins is often not more
than two orders of magnitude. In these interactions,
however, the control of the downstream event is based on
having the operator site on the DNA occupied and hence
repressing gene expression. Different concentrations of
protein will only affect the outcome if they drop below the
point where the operator is not occupied. Elevated con-
centrations above this have no effect on the biological
outcome. The transduction of a defined signal from one
protein to another in a linear manner requires a high level
of integrity, however. With many similar domains present
in the cell, over-expression of one can lead to competition
for the available binding sites. Two orders of magnitude
difference in affinity can even be considered promiscuous
because, for example, it represents the range exhibited by
the protein OppA for the binding of tripeptides. OppA
will bind peptides with any of the naturally occurring
amino acids in any of the three positions. As this protein is
involved in mopping up peptides in the bacterial
periplasm, it ideally should not show any specificity for its
ligands [15]. In the case of SH domains, is a difference in
affinity of two orders of magnitude enough to ensure that
only the specific interaction prevails? 
In a cellular context, specificity is not an intrinsic charac-
teristic of a protein interaction (such as affinity) but is a
relative characteristic defining the ability of a protein to
discriminate in favour of its cognate ligand. Given the fact
that more than 100 different SH2 and SH3 domains are
encoded by genes in eukaryotic cells, an SH domain has to
potentially compete for its ‘specific’ ligand against an
Table 2
Binding of peptides containing proline-rich motifs to SH3
domains from a range of proteins.
SH3 domain Peptide KD (µM) Reference
Abl RAPTMPPPLPP (3BP-1) 34 [24]
Abl PPAYPPPPVP (3BP-2) 5 [24]
Fyn PVRPQVPLRPPMT (Nef) 202 [12]
Fyn PPRPTPVAPGSSKT (p85) 50 [25]
Fyn HSIAGPPVPPR (Sos1-4) 20 [24]
Fyn RAPTMPPPLPP (3BP-1) 34 [24]
Fyn PPAYPPPPVP (3BP-2) 34 [24]
Fyn PPRPLPVPPGSSKT (p85) 16 [16]
Grb2 VPPPVPPRRR (Sos) 5 [26]
Grb2 GTDEVPVPPPVPPRRRPESA (hSos) 21 [27]
Hck PVRPQVPLRPPMT (Nef) 91 [15]
p85 RKLPPRPSK (libraries) 9 [28]
Src RALPPLPRY (libraries) 8 [29]
Src HSIAGPPVPPR (Sos1–4) 26 [24]
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ensemble of potentially 100 times more numerous non-
specific interactions, that is to say, the bulk of structurally
similar SH domains. If the nonspecific SH domains are in
concentrations equal to the specific SH domain, they will
therefore compete for the ligand and predominate in
binding, despite a difference of two orders of magnitude
in affinity. 
How might specificity be induced in SH domain signalling?
The fact that activation of a given signal transduction
pathway will produce a defined response suggests that
erroneous pathways could frequently be activated. As this
does not appear to be the case (or at least the outcomes of
these are not frequently apparent) the cell must have
mechanisms to combat such potentially deleterious effects.
Cellular co-localisation of proteins
Specificity only becomes an important issue if elevated
concentrations of nonspecific ligands can be found to
compete for the specific sites. Little is known about the
localised concentrations of proteins in cells. Some proteins
can potentially be compartmentalised by, for example, pH
gradients in the cell or by other proteins (e.g. chaperones).
The cell membrane itself can potentially give rise to high
local concentrations of given proteins. Proteins that bind
preferentially to a given lipid can be localised by the parti-
tion of lipids in the membrane into rafts. For example,
there is some evidence that activation of protein kinase C
is enhanced by lateral heterogeneities of lipids in the
membrane bilayer [16].
A way of maintaining mutual exclusivity in the absence of
high levels of specificity in the interactions of individual
domains, and one that is gaining wider acceptance in the
field, is to invoke the assembly of large signalling com-
plexes involving a multitude of interacting proteins.
Rather than a system of individual interactions of proteins
building up to produce a linear pathway, stimulation of a
membrane-bound receptor results in the recruitment of a
large number of proteins that assemble at the membrane.
The involvement of a number of proteins means that,
although the affinity of any given interaction might be low,
the presence of this protein is necessary for the complete
assembly and only once the correct assemblage of proteins
is in place will downstream signalling be affected. The
order of assembly, the time for which the complex prevails
and conformation of particular proteins in the complex are
likely to be of importance in the integrity of the signal.
The multi-protein aggregate therefore forms a gate to
signal transduction like a capacitor in an electric circuit.
Parallel processing of signalling pathways
Another way of circumventing the requirement for a high
level of specificity in any given SH domain interaction is
to invoke the parallel processing of signals. In this case the
activation of a receptor might recruit a protein containing a
modular domain. This protein can interact with more than
one downstream effector, which can result in the initiation
of more than one signalling pathway. For a signal to be
transduced, however, the pathways emanating from the
activated receptor ultimately converge on a protein that
forms a ‘junction’ in the pathways. One way in which any
aberrant pathways can be removed is if the downstream
signal from the junction protein can only be activated if
two or more incoming signals arrive at the junction protein
simultaneously. As the downstream effect of receptor acti-
vation will occur when both pathways are activated and
reach the junction protein, then this parallel processing of
signals can preclude activation of a pathway by the wrong
ligand. These junction proteins can therefore interact with
proteins from different signalling pathways.
The effect of multiple domains
In many proteins, SH2 and SH3 domains are juxtaposed
with other ligand-binding domains (reviewed in [17]). In
some cases it is clear that the combined effect of the inter-
action of two or more domains with a given ligand adds a
higher level of specificity [18]. This occurs not only from
the combined effect of the favourable free energies of inter-
action of the individual domains, but also from the steric
restrictions imposed on interactions by the relative posi-
tions of the domains. It is clear, however, that not all inter-
actions involve the effects of multiple domains; for
example, Grb2 binds to receptors with only its SH2 domain.
The adaptor protein links the β-adrenergic receptor with
c-Src via the SH3 domain of the latter protein [19]. The
SH2 domain of Src appears to play no role in this complex.
Implications for pharmaceutical research
The lack of specificity shown by both SH2 and SH3
domains might provide an explanation for the general
failure of the pharmaceutical industry to develop suitable
inhibitors of these interactions. Much effort has been
focused on the screening of SH domains for compounds to
interfere with defined signalling pathways. Originally,
these appeared to be highly suitable targets because an
appropriate compound could selectively knockout a spe-
cific aberrant pathway, whilst leaving other cell functions
unaffected. The lack of specificity might lead to any
potential drug compound interacting with numerous SH
domains in the cell with undesired effects.
On the basis of the low levels of specificity observed in the
interactions and the large number of proteins containing
SH domains that often play a crucial role in distinct sig-
nalling pathways, it seems that the integrity of signals has
to be guaranteed by mechanisms other than simple linear
transduction. Here we have tried to highlight the potential
inadequacies in invoking linear pathways to explain intra-
cellular signalling and attempted to highlight other more
complex mechanisms. To fully understand how higher
order structures or protein localisation processes might
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provide appropriate signalling requires a new approach to
experiments and, potentially, a different interpretation of
existing data.
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